Wednesday, July 8, 2026

Patent intelligence · US

US 12427125

Method for treating SARS and treating or preventing ARDS

granted A61KA61K31/167A61K31/19A61K31/192
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 7
Patent details — US 12427125
Jurisdiction
US
Status
granted
Grant date
Sep 30, 2025
Expiration
Sep 25, 2045
Claims
14
CPC classes
A61K, A61K31/167, A61K31/19, A61K31/192
View on Google Patents ↗

Quick answer

US 12427125 (Method for treating SARS and treating or preventing ARDS) is held by Aardvark Therapeutics, Inc.. Status: granted. Granted Sep 30, 2025. Expires Sep 25, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
14
CPC classes
A61K, A61K31/167, A61K31/19, A61K31/192, A61K31/215, A61K31/22

More from Aardvark Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12414934

    Combination therapies

    Aardvark Therapeutics, Inc. · Expires Sep 11, 2045

    granted
  2. US 12329739

    Isoflavonoid compounds and methods for the treatment of cancer

    Aardvark Therapeutics, Inc. · Expires Jun 12, 2045

    granted
  3. US 12318364

    Isoflavonoid compositions and methods for the treatment of cancer

    Aardvark Therapeutics, Inc. · Expires May 29, 2045

    granted
  4. US 12268660

    Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension

    Aardvark Therapeutics, Inc. · Expires Apr 3, 2045

    granted
  5. US 12201593

    Oral pharmaceutical formulations of bitter compounds for asthma

    Aardvark Therapeutics, Inc. · Expires Jan 16, 2045

    granted
  6. US 10835505

    Oral pharmaceutical formulation for weight loss, diabetes and related disorders

    Aardvark Therapeutics, Inc. · Expires Nov 12, 2040

    granted

Frequently asked questions

What is US patent 12427125?

US 12427125 (Method for treating SARS and treating or preventing ARDS) is held by Aardvark Therapeutics, Inc.. Status: granted. Granted Sep 30, 2025. Expires Sep 25, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12427125?

Aardvark Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.

When does US 12427125 expire?

Our index shows an expiration date of Sep 25, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.